|
|
Volumn 19, Issue 3, 2013, Pages 538-540
|
|
Changing the way we do business: Recommendations to accelerate biomarker development in pancreatic cancer
a
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
FLUOROURACIL;
GEMCITABINE;
PANCREAS ENZYME;
TUMOR MARKER;
ADJUVANT CHEMORADIOTHERAPY;
ADVANCED CANCER;
AUTOLYSIS;
BLOOD SAMPLING;
CANCER ADJUVANT THERAPY;
CANCER PROGNOSIS;
CANCER RESEARCH;
CANCER SURGERY;
CLINICAL PROTOCOL;
CYTOLOGY;
DETERIORATION;
EPITHELIUM;
FINE NEEDLE ASPIRATION BIOPSY;
GASTROENTEROLOGY;
GENE SEQUENCE;
HUMAN;
MEDICAL TECHNOLOGY;
METASTASIS;
MOLECULAR BIOLOGY;
NATIONAL HEALTH ORGANIZATION;
PANCREAS ADENOCARCINOMA;
PANCREAS CANCER;
PATHOLOGIST;
PATIENT CARE;
PATIENT COMPLIANCE;
PHASE 3 CLINICAL TRIAL (TOPIC);
PHYSICIAN ATTITUDE;
POLICY;
PRIORITY JOURNAL;
RESOURCE MANAGEMENT;
REVIEW;
THERAPY DELAY;
TISSUE MICROARRAY;
TISSUE PRESERVATION;
TISSUE SECTION;
TUMOR BIOPSY;
WORKFLOW;
BIOLOGICAL SPECIMEN BANKS;
CARCINOMA, PANCREATIC DUCTAL;
CLINICAL TRIALS AS TOPIC;
HUMANS;
PANCREATIC NEOPLASMS;
TUMOR MARKERS, BIOLOGICAL;
|
|
EID: 84873361771
PISSN: 10780432
EISSN: 15573265
Source Type: Journal
DOI: 10.1158/1078-0432.CCR-12-2745 Document Type: Review |
|
Times cited : (18)
|
|
References (5)
|
